Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2013

Open Access 01-12-2013 | Review

Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review

Authors: Crisanta I Tapia, Kristin Khalaf, Karina Berenson, Denise Globe, Michael Chancellor, Lesley K Carr

Published in: Health and Quality of Life Outcomes | Issue 1/2013

Login to get access

Abstract

Background

Patients with neurologic diseases often have neurogenic detrusor overactivity (NDO), which can result in a loss of voluntary bladder control and uncontrollable urinary incontinence (UI).The impact of UI due to NDO on patients’ lives has not been well studied. The objective of this review was to assess the health-related quality of life (HRQoL) and economic burden in patients with urgency UI due to NDO in select countries in North America, the European Union, Asia, and Australia.

Methods

Systematic literature searches and reviews of articles published in English (January 2000 to February 2011) were conducted using MEDLINE®, EMBASE®, and the Cochrane Library. Studies assessing the impact of UI on HRQoL of patients with an underlying neurologic condition of interest (i.e., multiple sclerosis, spinal cord injury, Parkinson’s disease, stroke, or spina bifida) were included. Economic studies in urgency UI also were included.

Results

Of 876 citations generated in the initial search, a total of 27 articles were deemed relevant: 16 articles presented HRQoL data and 11 articles presented information on the economic burden of UI. Humanistic studies used a range of HRQoL instruments to measure HRQoL burden, and the economic studies included different cost components to quantify the economic burden, making meaningful comparisons challenging. Despite this heterogeneity, the literature suggests that HRQoL in patients with UI due to NDO is worse than patients with UI in general or those with the same underlying neurologic condition without UI. In addition, urgency UI also results in substantial economic costs.

Conclusions

Incontinent patients with underlying neurologic conditions have impaired HRQoL as well as substantial economic burden attributable to UI due to NDO. There is a need for urgency UI treatments that improve HRQoL of these patients and alleviate the economic burden of this condition.
Appendix
Available only for authorised users
Literature
1.
Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, Cottenden A, Davila W, de Ridder D, Dmochowski R: Fourth International consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010, 29: 213–240. 10.1002/nau.20870PubMedCrossRef
2.
Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring EL Jr, Nguyen-Khoa BA, Jones JK: Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn 2011, 30: 395–401. 10.1002/nau.21003PubMedCrossRef
3.
Johansson C, Molander U, Milsom I, Ekelund P: Association between urinary incontinence and urinary tract infections, and fractures in postmenopausal women. Maturitas 1996, 23: 265–271. 10.1016/0378-5122(95)00982-5PubMedCrossRef
4.
Wagner TH, Hu TW, Bentkover J, LeBlanc K, Stewart W, Corey R, Zhou Z, Hunt T: Health-related consequences of overactive bladder. Am J Managed Care 2002, 8: S598–607.
5.
Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N: Falls in outpatients with Parkinson’s disease: frequency, impact and identifying factors. J Neurol 2005, 252: 1310–1315. 10.1007/s00415-005-0855-3PubMedCrossRef
6.
Harpe SE, Szeinbach SL, Caswell RJ, Corey R, McAuley JW: The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder. J Urol 2007, 178: 2532–2536. discussion 2536 10.1016/j.juro.2007.08.006PubMedCrossRef
7.
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ: Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20: 327–336.PubMed
8.
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50: 1306–1314. discussion 1314–1305 10.1016/j.eururo.2006.09.019PubMedCrossRef
9.
10.
Betts CD, D’Mellow MT, Fowler CJ: Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993, 56: 245–250. 10.1136/jnnp.56.3.245PubMedCrossRef
11.
Berger Y, Blaivas JG, DeLaRocha ER, Salinas JM: Urodynamic findings in Parkinson’s disease. J Urol 1987, 138: 836–838.PubMed
12.
13.
14.
15.
Wefer B, Ehlken B, Bremer J, Burgdorfer H, Domurath B, Hampel C, Kutzenberger J, Seif C, Sievert KD, Berger K, Pannek J: Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol 2010, 28: 385–390. 10.1007/s00345-009-0466-1PubMedCrossRef
16.
Forbes A, While A, Mathes L, Griffiths P: Health problems and health-related quality of life in people with multiple sclerosis. Clin Rehabil 2006, 20: 67–78. 10.1191/0269215506cr880oaPubMedCrossRef
17.
Goris S, Sungur G, Tasci S, Mirza M, Ceyhan O, Tekinsoy P: The effect of urinary incontinence and sexual dysfunction on the quality of life among women with multiple sclerosis. Pak J Med Sci 2010, 26: 277–281.
18.
Khan F, Pallant JF, Shea TL: Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil 2009, 31: 1567–1576. 10.1080/09638280802639566PubMedCrossRef
19.
Quarto G, Autorino R, Gallo A, De Sio M, D’Armiento M, Perdonà S, Damiano R: Quality of life in women with multiple sclerosis and overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2007, 18: 189–194.PubMedCrossRef
20.
Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Maruish ME: User’s Manual for the SF-36v2™ Health Survey. 2nd edition. Lincoln, RI, USA: QualityMetric; 2007.
21.
Liu CW, Attar KH: The relationship between bladder management and health-related quality of life in pts with spinal cord injury in the UK. Spinal Cord 2010., 48:
22.
Oh SJ, Ku JH, Jeon HG, Shin HI, Paik NJ, Yoo T: Health-related quality of life of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Urology 2005, 65: 306–310. 10.1016/j.urology.2004.09.032PubMedCrossRef
23.
Hollingworth W, Campbell JD, Kowalski J, Ravelo A, Girod I, Briggs A, Sullivan SD: Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Qual Life Res 2010, 19: 323–331. 10.1007/s11136-010-9590-zPubMedCrossRef
24.
Valtonen K, Karlsson AK, Siosteen A, Dahlof LG, Viikari-Juntura E: Satisfaction with sexual life among persons with traumatic spinal cord injury and meningomyelocele. Disabil Rehabil 2006, 28: 965–976. 10.1080/09638280500404362PubMedCrossRef
25.
Iacovelli E, Gilio F, Meco G, Fattapposta F, Vanacore N, Brusa L, Giacomelli E, Gabriele M, Rubino A, Locuratolo N: Bladder symptoms assessed with overactive bladder questionnaire in Parkinson’s disease. Mov Disord 2010, 25: 1203–1209. 10.1002/mds.23093PubMedCrossRef
26.
Pohar SL, Allyson Jones C: The burden of Parkinson disease (PD) and concomitant comorbidities. Arch Gerontol Geriatr 2009, 49: 317–321. 10.1016/j.archger.2008.11.006PubMedCrossRef
27.
Edwards DF, Hahn M, Dromerick A: Post stroke urinary loss, incontinence and life satisfaction: when does post-stroke urinary loss become incontinence? Neurourol Urodyn 2006, 25: 39–45. 10.1002/nau.20199PubMedCrossRef
28.
Tibaek S, Gard G, Klarskov P, Iversen HK, Dehlendorff C, Jensen R: Are activity limitations associated with lower urinary tract symptoms in stroke patients? A cross-sectional, clinical survey. Scand J Urol Nephrol 2009, 43: 383–389. 10.3109/00365590903013919PubMedCrossRef
29.
Kolominsky-Rabas PL, Hilz MJ, Neundoerfer B, Heuschmann PU: Impact of urinary incontinence after stroke: results from a prospective population-based stroke register. Neurourol Urodyn 2003, 22: 322–327. 10.1002/nau.10114PubMedCrossRef
30.
Patel M, Coshall C, Lawrence E, Rudd AG, Wolfe CD: Recovery from poststroke urinary incontinence: associated factors and impact on outcome. J Am Geriatr Soc 2001, 49: 1229–1233. 10.1046/j.1532-5415.2001.49242.xPubMedCrossRef
31.
Patel M, Coshall C, Rudd AG, Wolfe CD: Natural history and effects on 2-year outcomes of urinary incontinence after stroke. Stroke 2001, 32: 122–127. 10.1161/01.STR.32.1.122PubMedCrossRef
32.
Lemelle JL, Guillemin F, Aubert D, Guys JM, Lottmann H, Lortat-Jacob S, Mouriquand P, Ruffion A, Moscovici J, Schmitt M: Quality of life and continence in patients with spina bifida. Qual Life Res 2006, 15: 1481–1492. 10.1007/s11136-006-0032-xPubMedCrossRef
33.
Morris AR, Ho MT, Lapsley H, Walsh J, Gonski P, Moore KH: Costs of managing urinary and faecal incontinence in a sub-acute care facility: a “bottom-up” approach. Neurourol Urodyn 2005, 24: 56–62. 10.1002/nau.20079PubMedCrossRef
34.
Green JP, Smoker I, Ho MT, Moore KH: Urinary incontinence in subacute care–a retrospective analysis of clinical outcomes and costs. Med J Aust 2003, 178: 550–553.PubMed
35.
Papanicolaou S, Pons ME, Hampel C, Monz B, Quail D, Schulenburg MG, Wagg A, Sykes D: Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study. Maturitas 2005, 52 Suppl 2: S35-S47.PubMedCrossRef
36.
Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C: The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2008, 103: 202–209.CrossRef
37.
Tediosi F, Parazzini F, Bortolotti A, Garattini L: The cost of urinary incontinence in Italian women. A cross-sectional study. Gruppo di Studio Incontinenza. Pharmacoeconomics 2000, 17: 71–76. 10.2165/00019053-200017010-00005PubMedCrossRef
38.
Thom DH, Nygaard IE, Calhoun EA: Urologic diseases in America project: urinary incontinence in women-national trends in hospitalizations, office visits, treatment and economic impact. J Urol 2005, 173: 1295–1301. 10.1097/01.ju.0000155679.77895.cbPubMedCrossRef
39.
Frantz RA, Xakellis GC Jr, Harvey PC, Lewis AR: Implementing an incontinence management protocol in long-term care. Clinical outcomes and costs. J Gerontol Nurs 2003, 29: 46–53.PubMedCrossRef
40.
Shih YC, Hartzema AG, Tolleson-Rinehart S: Labor costs associated with incontinence in long-term care facilities. Urology 2003, 62: 442–446. 10.1016/S0090-4295(03)00485-0PubMedCrossRef
41.
Prasopsanti K, Santi-Ngamkun A, Pornprasit K: Estimated cost of overactive bladder in Thailand. J Med Assoc Thai 2007, 90: 2316–2320.PubMed
42.
Subak LL, Brown JS, Kraus SR, Brubaker L, Lin F, Richter HE, Bradley CS, Grady D: The “costs” of urinary incontinence for women. Obstet Gynecol 2006, 107: 908–916. 10.1097/01.AOG.0000206213.48334.09PubMedCrossRef
43.
Mahajan ST, Patel PB, Marrie RA: Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol 2010, 183: 1432–1437. 10.1016/j.juro.2009.12.029PubMedCrossRef
44.
45.
Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED: A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998, 4: 419–425.PubMedCrossRef
46.
Stöhrer M, Castro-Diaz D, Chartier-Kastler E, Kramer G, Mattiasson A, Wyndaele JJ: Guidelines on Neurogenic Lower Urinary Tract Dysfunction. Arnhem, the Netherlands: European Association of Urology (EAU); 2003.
47.
Kay GG, Granville LJ: Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005, 27: 127–138. quiz 139–140 10.1016/j.clinthera.2005.01.006PubMedCrossRef
Metadata
Title
Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review
Authors
Crisanta I Tapia
Kristin Khalaf
Karina Berenson
Denise Globe
Michael Chancellor
Lesley K Carr
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2013
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-11-13

Other articles of this Issue 1/2013

Health and Quality of Life Outcomes 1/2013 Go to the issue

Research

Association between sense of coherence and health-related quality of life among primary care patients with chronic musculoskeletal pain

Research

Anticipated adaptation or scale recalibration?

Research

Health-related quality of life and survival in Chinese patients with chronic liver disease

Research

Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA

Research

Linguistic and psychometric validation of the Chinese version of the Glaucoma Quality of Life-15 (GQL-15-CHI): a cross-sectional study

Research

Psychometric properties of the Chinese version of the pediatric quality of life inventory 4.0 Generic core scales among children with short stature